01
Sep,2023
News

AcadeMab Biomedical and Academia Sinica enter into exclusive license agreement for dengue fever mRNA vaccine and Potent cationic lipids

 
Academia Sinica and AcadeMab Biomedical have reached an exclusive licensing agreement. The project includes dengue fever mRNA vaccine and a series of novel cationic lipids. Under the terms of the agreement, AcadeMab will establish a new "mRNA Vaccine R&D Department" for the development, manufacturing of dengue mRNA vaccine and implementing pre-clinical and clinical trials as well as commercializing cationic lipids.

As the global dengue fever epidemic continues to rise, AcadeMab is making the commitment to human health by providing effective and safer dengue fever vaccine via mRNA technology in the short term. In addition, AcadeMab will leverage its cationic lipid platform to lower the barriers to developing mRNA delivery technology and help create an ecosystem for mRNA vaccine manufacturing.

BACK


Verification

Click the numbers in sequence.

academab.com may set and access academab.com cookies on your computer.  Cookies are used to provide our system with the basic information to provide the services you are requesting.  Cookies can be cleared at any time from your internet browser settings. 

 

Cookies Cookies

Privacy preference center

academab.com may set and access academab.com cookies on your computer.  Cookies are used to provide our system with the basic information to provide the services you are requesting.  Cookies can be cleared at any time from your internet browser settings. 

 

Privacy Privacy

Manage Consent Settings

Necessary Cookies

Enable All

網站運行離不開這些 Cookie 且您不能在系統中將其關閉。通常僅根據您所做出的操作(即服務請求)來設置這些 Cookie,如設置隱私偏好、登錄或填充表格。您可以將您的瀏覽器設置為阻止或向您提示這些 Cookie,但可能會導致某些網站功能無法工作。